The drugmaker made a net profit of nearly $22bn last year, up from $9.1bn in 2020, on $81.3 billion in sales, including $37bn in vaccine sales
The US drugmaker’s overall revenues in 2021 doubled to $81.3bn, and it expects to make record revenues of $98bn to $102bn this year.
The bumper sales prompted accusations from campaigners of “pandemic profiteering”. The group Global Justice Now said the annual revenue of $81bn was more than the GDP of most countries and accused Pfizer of “ripping off public health systems”.
The Covid jab Comirnaty, which the New-York based pharma firm developed with the much smaller German company BioNTech, brought in $12.5bn in revenues in the final quarter of 2021, taking the total for the year to $36.8bn. Pfizer said it had exceeded its target of manufacturing 3bn doses of the vaccine last year.
It increased its 2022 estimate for Comirnaty sales to $32bn and expects Paxlovid to contribute $22bn in revenues.
© Copyright LaPresse